Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the immunological response rate to administration of
the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated
with aromatase inhibitors or Faslodex® and who do not require chemotherapy.
Post-menopausal women on aromatase inhibitors or Faslodex® alone and pre-menopausal women on
aromatase inhibitors plus luteinising hormone-releasing hormone (LH/RH)-agonist may be
eligible to be enrolled.
Patients must not have had radiotherapy or major surgery within four (4) weeks prior to
entering the study.
Information about the safety and tolerability of administration of the THERATOPE® vaccine
will also be gathered during the course of the study.